Kirax Corporation, formerly known as Tigris Pharmaceuticals, focuses on acquiring, developing and commercializing innovative specialty care therapies with emphasis on oncology, pain, inflammation, acute and supportive care.

Building on its core competencies in clinical development, regulatory affairs, safety and commercialization, Kirax licenses or acquires rights to compounds in various stages of clinical development as well as in-market products.